Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

J. Randolph Hecht; Charles D. Blanke; A. B. Benson; Heinz J. Lenz

Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

J. Randolph Hecht^*, Charles D. Blanke, A. B. Benson, Heinz J. Lenz

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.

Original language	English (US)
Pages (from-to)	13-15
Number of pages	3
Journal	Oncology (Williston Park, N.Y.)
Volume	17
Issue number	9 Suppl 8
State	Published - Sep 2003

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ef836481d6ca4276a35695594cfe37ea,

title = "Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.",

abstract = "Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.",

author = "Hecht, {J. Randolph} and Blanke, {Charles D.} and Benson, {A. B.} and Lenz, {Heinz J.}",

year = "2003",

month = sep,

language = "English (US)",

volume = "17",

pages = "13--15",

journal = "Oncology",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "9 Suppl 8",

}

TY - JOUR

T1 - Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

AU - Hecht, J. Randolph

AU - Blanke, Charles D.

AU - Benson, A. B.

AU - Lenz, Heinz J.

PY - 2003/9

Y1 - 2003/9

N2 - Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.

AB - Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.

UR - http://www.scopus.com/inward/record.url?scp=1542465993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542465993&partnerID=8YFLogxK

M3 - Article

C2 - 14569841

AN - SCOPUS:1542465993

SN - 0890-9091

VL - 17

SP - 13

EP - 15

JO - Oncology

JF - Oncology

IS - 9 Suppl 8

ER -

Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this